Lorus Therapeutics Inc. is a biopharmaceutical company focused on the research and development of pharmaceutical products and technologies for the management of cancer. The company today announced the presentation of its phase II clinical trial data for LOR-2040 in combination with high dose cytarabine for the treatment of Acute Myeloid Leukemia (AML).
The data was given at the 15th Annual Congress of the European Hematology Association (EHA) in Barcelona, Spain in a presentation entitled “A Phase II Study of GTI-2040, an Antisense to Ribonucleotide Reductase (NYSE:RNR), in Combination with High-Dose Cytarabine (HiDAC) in Relapsed and Refractory Acute Myeloid Leukemia (AML).”
The presentation discussed the safety and efficacy data from the recently completed phase II clinical trial, which was conducted at six major U.S. cancer centers.
The phase II study involved 25 patients under 60 years of age with relapsed or refractory AML treated with HiDAC and LOR-2040. According to the press release, 28 percent of the patients achieved complete remission (NYSE:CR) or CR with incomplete blood count recovery (CRi) while one patient (4 percent) achieved partial remission.
For more information visit: lorusthera.com
Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
Disclosure: no positions